Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

MLA

Berthold, Frank, et al. “Myeloablative Megatherapy with Autologous Stem-Cell Rescue versus Oral Maintenance Chemotherapy as Consolidation Treatment in Patients with High-Risk Neuroblastoma: A Randomised Controlled Trial.” The Lancet. Oncology, vol. 6, no. 9, Sept. 2005, pp. 649–58. EBSCOhost, https://doi.org/10.1016/S1470-2045(05)70291-6.

APA

Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., Simon, T., & Hero, B. (2005). Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The Lancet. Oncology, 6(9), 649–658. https://doi.org/10.1016/S1470-2045(05)70291-6

Chicago

Berthold, Frank, Joachim Boos, Stefan Burdach, Rudolf Erttmann, Günter Henze, Johann Hermann, Thomas Klingebiel, et al. 2005. “Myeloablative Megatherapy with Autologous Stem-Cell Rescue versus Oral Maintenance Chemotherapy as Consolidation Treatment in Patients with High-Risk Neuroblastoma: A Randomised Controlled Trial.” The Lancet. Oncology 6 (9): 649–58. doi:10.1016/S1470-2045(05)70291-6.